773,158 Shares in ADMA Biologics Inc $ADMA Purchased by Boothbay Fund Management LLC

Boothbay Fund Management LLC acquired a new position in ADMA Biologics Inc (NASDAQ:ADMA) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 773,158 shares of the biotechnology company’s stock, valued at approximately $11,334,000.

Several other large investors have also modified their holdings of the business. Quadrant Capital Group LLC grew its stake in shares of ADMA Biologics by 3.9% during the second quarter. Quadrant Capital Group LLC now owns 16,660 shares of the biotechnology company’s stock valued at $303,000 after buying an additional 629 shares during the last quarter. Cim LLC lifted its stake in shares of ADMA Biologics by 0.7% during the 3rd quarter. Cim LLC now owns 91,486 shares of the biotechnology company’s stock worth $1,341,000 after acquiring an additional 665 shares during the last quarter. Smartleaf Asset Management LLC boosted its holdings in ADMA Biologics by 28.9% during the 2nd quarter. Smartleaf Asset Management LLC now owns 3,118 shares of the biotechnology company’s stock valued at $57,000 after acquiring an additional 700 shares during the period. Clearstead Advisors LLC boosted its holdings in ADMA Biologics by 55.7% during the 3rd quarter. Clearstead Advisors LLC now owns 2,222 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 795 shares during the period. Finally, Oppenheimer & Co. Inc. grew its position in ADMA Biologics by 1.7% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 49,230 shares of the biotechnology company’s stock valued at $722,000 after acquiring an additional 835 shares during the last quarter. Hedge funds and other institutional investors own 75.68% of the company’s stock.

Insider Buying and Selling at ADMA Biologics

In related news, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of the company’s stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $15.63, for a total value of $157,800.48. Following the completion of the sale, the chief operating officer directly owned 466,600 shares of the company’s stock, valued at $7,292,958. This represents a 2.12% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Steve Elms bought 7,000 shares of the company’s stock in a transaction on Thursday, March 5th. The shares were acquired at an average price of $15.67 per share, for a total transaction of $109,690.00. Following the completion of the acquisition, the director owned 2,038,730 shares in the company, valued at $31,946,899.10. This represents a 0.34% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Company insiders own 3.50% of the company’s stock.

ADMA Biologics Stock Up 1.1%

Shares of NASDAQ:ADMA opened at $15.15 on Friday. The business’s 50 day moving average is $16.63 and its 200 day moving average is $16.71. The stock has a market cap of $3.61 billion, a P/E ratio of 25.25 and a beta of 0.51. ADMA Biologics Inc has a 52-week low of $13.76 and a 52-week high of $25.67. The company has a quick ratio of 3.74, a current ratio of 6.71 and a debt-to-equity ratio of 0.16.

ADMA Biologics (NASDAQ:ADMA) last issued its earnings results on Wednesday, February 25th. The biotechnology company reported $0.20 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.20. ADMA Biologics had a return on equity of 37.52% and a net margin of 28.80%.The business had revenue of $139.16 million during the quarter, compared to analyst estimates of $139.80 million. During the same period in the previous year, the company posted $0.46 EPS. ADMA Biologics’s revenue was up 18.4% on a year-over-year basis. Sell-side analysts predict that ADMA Biologics Inc will post 0.51 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have weighed in on ADMA. Zacks Research upgraded ADMA Biologics from a “hold” rating to a “strong-buy” rating in a research note on Monday, March 2nd. Weiss Ratings reissued a “hold (c)” rating on shares of ADMA Biologics in a research note on Tuesday, December 23rd. Finally, Wall Street Zen raised shares of ADMA Biologics from a “hold” rating to a “buy” rating in a research note on Saturday, February 28th. Two research analysts have rated the stock with a Strong Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, ADMA Biologics currently has a consensus rating of “Buy” and a consensus target price of $32.00.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.